Pasithea Therapeutics to Call Special Meeting of Stockholders - Seite 2

Forward Looking Statements

This press release contains statements that constitute “forward-looking statements.” Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company’s filings with the SEC. Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law. Such forward-looking statements are subject to risks (including those set forth in the Company’s Form 10-K for the fiscal year ended December 31, 2021, as amended, filed with the U.S. Securities and Exchange Commission) and uncertainties which could cause actual results to differ from the forward-looking statements.

Important Additional Information and Where to Find It

This communication may be deemed solicitation material in respect of the Special Meeting. The Company plans to file a proxy statement with the Securities and Exchange Commission, in connection with the solicitation of proxies for the Special Meeting. Stockholders are urged to read such proxy statement (including any amendments or supplements thereto) and any other relevant documents that the Company files with the SEC carefully in their entirety when they become available because they will contain important information.

Certain Information Regarding Participants to the Solicitation

Pasithea, its directors and certain of its executive officers and employees are deemed to be participants in a solicitation of requests not to vote for the Camac Group’s proposal at the Special Meeting (the “Special Meeting Solicitation”). Information regarding the identity of these potential participants and their direct or indirect interests, by security holdings or otherwise, is set forth in the Consent Revocation Solicitation Statement filed by Pasithea with the Securities and Exchange Commission on July 28, 2022.